Pharmacoepidemiology and Drug Safety · 2012 · 41 citations · 7 references
PharmacyPharmacotherapyPsychiatryClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyMedication UsePharmacoepidemiologySchizophrenia PharmacotherapyAntipsychotic Medication ManagementAntipsychotic Medication UseAntipsychotic SafetyAntipsychotic WithdrawalRegistersTherapeutic Benefit-risk Assessment
OBJECTIVE: Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated. METHODS: Nationwide registers in Finland were utilized to study thioridazine use, hospitalization rate and length of hospital stay. RESULTS: Although thioridazine use continued to diminish year after year, the hospitalization rate remained constant until the withdrawal year of 2005, when the percentage of patients hospitalized for schizophrenia doubled. CONCLUSION: The market withdrawal of thioridazine predisposed many stable patients towards psychotic relapses. In order to minimize this kind of risk, an overall risk-benefit assessment and a clear-cut plan for the replacement of an antipsychotic should be established before market withdrawal.
7
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
JG Reilly, I. Nicol Ferrier, SJ Jones et al. · The Lancet · 2000 · 606 citations
Medicine, Pharmacology, Psychiatry +15
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
T.M. Sanger, Jeffery A. Lieberman, Mauricio Tohen et al. · American Journal of Psychiatry · 1999 · 216 citations
Robin Emsley, J. Raniwalla, Peter J. Bailey et al. · International Clinical Psychopharmacology · 2000 · 177 citations
Thioridazine and sudden unexplained death in psychiatric in-patients
J. Reilly, Salma Ayis, I. Nicol Ferrier et al. · The British Journal of Psychiatry · 2002 · 156 citations · Full text
Medicine, Pharmacology, Psychiatry +13